DK3566703T3 - Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol - Google Patents
Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol Download PDFInfo
- Publication number
- DK3566703T3 DK3566703T3 DK19168102.2T DK19168102T DK3566703T3 DK 3566703 T3 DK3566703 T3 DK 3566703T3 DK 19168102 T DK19168102 T DK 19168102T DK 3566703 T3 DK3566703 T3 DK 3566703T3
- Authority
- DK
- Denmark
- Prior art keywords
- imidazol
- methylphenyl
- methanol
- ethyl
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15249409P | 2009-02-13 | 2009-02-13 | |
EP17174959.1A EP3241553B1 (en) | 2009-02-13 | 2010-02-12 | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3566703T3 true DK3566703T3 (da) | 2021-07-05 |
Family
ID=42083967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19168102.2T DK3566703T3 (da) | 2009-02-13 | 2010-02-12 | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
Country Status (9)
Country | Link |
---|---|
US (3) | US20110301214A1 (da) |
EP (3) | EP2395999B1 (da) |
JP (1) | JP2012518007A (da) |
AU (1) | AU2010213580A1 (da) |
CA (1) | CA2752148A1 (da) |
DK (1) | DK3566703T3 (da) |
ES (3) | ES2733905T3 (da) |
HK (1) | HK1246204B (da) |
WO (1) | WO2010093930A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
JP2013542991A (ja) | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | (3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル)メタノールを含む医薬組成物 |
CA2842866A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
US9095576B2 (en) | 2011-11-21 | 2015-08-04 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
WO2024145347A1 (en) * | 2022-12-27 | 2024-07-04 | Alceptor Therapeutics, Inc. | (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treatment of agitation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US5344840A (en) | 1988-02-29 | 1994-09-06 | Orion-Yhtyma Oy | 4-substituted imidazole derivatives useful in perioperative care |
GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
JP2013542991A (ja) | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | (3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル)メタノールを含む医薬組成物 |
US9095576B2 (en) | 2011-11-21 | 2015-08-04 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
-
2010
- 2010-02-12 EP EP10706824.9A patent/EP2395999B1/en active Active
- 2010-02-12 JP JP2011550276A patent/JP2012518007A/ja active Pending
- 2010-02-12 AU AU2010213580A patent/AU2010213580A1/en not_active Abandoned
- 2010-02-12 ES ES17174959T patent/ES2733905T3/es active Active
- 2010-02-12 CA CA2752148A patent/CA2752148A1/en not_active Abandoned
- 2010-02-12 DK DK19168102.2T patent/DK3566703T3/da active
- 2010-02-12 ES ES19168102T patent/ES2880578T3/es active Active
- 2010-02-12 EP EP19168102.2A patent/EP3566703B1/en active Active
- 2010-02-12 ES ES10706824.9T patent/ES2649018T3/es active Active
- 2010-02-12 US US13/147,760 patent/US20110301214A1/en not_active Abandoned
- 2010-02-12 EP EP17174959.1A patent/EP3241553B1/en active Active
- 2010-02-12 WO PCT/US2010/024111 patent/WO2010093930A1/en active Application Filing
-
2014
- 2014-11-21 US US14/550,647 patent/US9193690B2/en active Active
-
2015
- 2015-10-19 US US14/886,457 patent/US9555021B2/en active Active
-
2018
- 2018-05-08 HK HK18105920.4A patent/HK1246204B/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20110301214A1 (en) | 2011-12-08 |
ES2733905T3 (es) | 2019-12-03 |
US20150080445A1 (en) | 2015-03-19 |
EP3566703B1 (en) | 2021-04-07 |
CA2752148A1 (en) | 2010-08-19 |
HK1246204B (zh) | 2020-02-07 |
EP3241553A1 (en) | 2017-11-08 |
ES2880578T3 (es) | 2021-11-24 |
JP2012518007A (ja) | 2012-08-09 |
US9555021B2 (en) | 2017-01-31 |
US9193690B2 (en) | 2015-11-24 |
ES2649018T3 (es) | 2018-01-09 |
US20160038466A1 (en) | 2016-02-11 |
EP3566703A1 (en) | 2019-11-13 |
EP3241553B1 (en) | 2019-04-10 |
EP2395999A1 (en) | 2011-12-21 |
WO2010093930A1 (en) | 2010-08-19 |
AU2010213580A1 (en) | 2011-09-08 |
EP2395999B1 (en) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2020036I1 (el) | Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p | |
BRPI0914746A2 (pt) | composições fungicidas | |
DK2080901T3 (da) | Vindmølle-vindmålings-kompensation | |
DK2285411T3 (da) | Nikotintabletsammensætninger | |
BRPI0923433A2 (pt) | Síntese de compostos fucosilados | |
DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
HK1246204B (zh) | 包含(3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基)甲醇的藥物組合物 | |
BRPI0918602A2 (pt) | composto (i) | |
ITVR20080024A1 (it) | Struttura di tramoggia | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
DK3300729T3 (da) | Terapeutiske sammensætninger indeholdende macitentan | |
DK3338777T3 (da) | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme | |
BR112012002336A2 (pt) | compostos aza-heterocíclicos | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0820198A2 (pt) | composições farmacêuticas | |
BRPI0912171A2 (pt) | composição farmacêutica | |
FR2928356B1 (fr) | Distributeur de comprimes | |
DK2467136T3 (da) | 4-methylpyrazolformuleringer | |
BRPI0823402A2 (pt) | Formulações farmacêuticas de olmesartan | |
SMT201500123B (it) | Dosaggio unitario di apadenoson | |
BRPI0921301A2 (pt) | composição farmacêutica | |
BRPI0907824A2 (pt) | Ingrediente de oligossacarídeo | |
IL226384A (en) | Pharmaceuticals containing (3 - (1 - (1h - imidazole-4-yl) ethyl) -2-methylphenyl) methanol | |
BRPI0924828A2 (pt) | Ingrediente oligossacarídeo |